Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr Usmani on Identifying High-Risk Patients With Multiple Myeloma

September 15th 2023

Saad Z. Usmani, MD, MBA, FACP, discusses methods for identifying patients with high-risk multiple myeloma and notable disease characteristics in this population.

Dr Chari on the Use of Ide-Cel and Cilta-Cel in Relapsed/Refractory Multiple Myeloma

September 14th 2023

Ajai Chari, MD, discusses the use of the CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in the treatment of patients with multiple myeloma.

Extended Melphalan Flufenamide Indication Approaches EU Approval for R/R Multiple Myeloma

September 14th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding a Type II variation application to extend the therapeutic indication of melphalan flufenamide for use in adult patients with multiple myeloma who have received at least 2 prior lines of treatment and whose disease is refractory to lenalidomide and the last line of therapy.

Dr Richardson on the Potential Significance of Mezigdomide in Relapsed/Refractory Multiple Myeloma

September 12th 2023

Paul G. Richardson, MD, discusses how the continued development of the novel agent mezigdomide could affect the treatment paradigm for patients who progressed on, and developed resistance to, other available BCMA-directed therapies.

Dr Costa on the Clinical Implications of the MASTER Trial in Multiple Myeloma

September 11th 2023

Luciano J. Costa, MD, PhD, discusses clinical implications derived from a final analysis of the phase 2 MASTER trial, which evaluated quadruplet induction therapy in multiple myeloma.

FDA Approves Motixafortide Plus Filgrastim for ASCT in Multiple Myeloma

September 11th 2023

The FDA has approved motixafortide (Aphexda) in combination with filgrastim (Neupogen) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous stem cell transplant in patients with multiple myeloma.

Educating Patients on Treatment Options for Multiple Myeloma

September 11th 2023

Expert panelists consider best methods in educating patients on their options for therapy following a diagnosis of multiple myeloma.

Treatment for Newly Diagnosed Multiple Myeloma: Addressing Disparities in Care

September 11th 2023

Comprehensive insight to disparities that may impact a patient’s access to therapy for multiple myeloma and how these may be overcome.

Dr Deol on Potential Avenues for CAR T-Cell Therapy Research in Multiple Myeloma

September 8th 2023

Abhinav Deol, MD, discusses ongoing and potential research avenues for improving the use of CAR T-cell therapy in multiple myeloma.

Chari Highlights Nuances of Choosing Between CAR T-cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

September 8th 2023

Without a plethora of randomized and historic data to compare treatments, selection and sequencing strategies for patients with relapsed/refractory multiple myeloma must balance a multitude of factors, including adverse effect profiles, disease resistance mechanisms, and more.

Sustained MRD Negativity With Cilta-Cel Leads to Deep Responses in Relapsed/Refractory Multiple Myeloma

September 8th 2023

Minimal residual disease negativity sustained for 6 months or longer with ciltacabtagene autoleucel prolonged duration of response and progression-free survival compared with minimal residual disease negativity sustained for less than 6 months in patients with heavily pretreated relapsed/refractory multiple myeloma.

Dr Deol on Sequencing Treatment Options With CAR T-Cell Therapy in Multiple Myeloma

September 8th 2023

Abhinav Deol, MD, discusses the sequencing of CAR T-cell therapies with other readily available agents in multiple myeloma.

Dr Lin on the Outcomes of MRD-Negative Patients With R/R Myeloma After Cilta-Cel

September 7th 2023

Yi Lin, MD, PhD, discusses the patient characteristic for those with relapsed/refractory multiple myeloma who experienced sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel during the phase 1/2 CARTITUDE-1 trial.

Dr Lin on the Characteristics of Patients With Multiple Myeloma and Sustained MRD Negativity in CARTITUDE-1

September 7th 2023

Yi Lin, MD, PhD, the predictive value of baseline characteristics in relation to sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

September 4th 2023

Dr Usmani discusses the integration of elranatamab, talquetamab, and telcistamab into the management of relapsed/refractory multiple myeloma, common adverse effects and recommended supportive care measures, and ongoing research that may help clarify their role in the paradigm.

Treatment Considerations for Patients with Newly Diagnosed Multiple Myeloma

September 4th 2023

Panelists share a brief discussion on the current treatment armamentarium available to patients with newly diagnosed multiple myeloma.

Role of Diagnostic Testing in Patients with Multiple Myeloma

September 4th 2023

Experts in multiple myeloma management consider essential tests that aid in the diagnosis and treatment of newly presenting patients.

Dr Tauro on the Rationale for Investigating ULK3 in Multiple Myeloma

September 1st 2023

Marilena Tauro, PhD, discusses the investigation of ULK3 in patients with multiple myeloma.

Mezigdomide Plus Dexamethasone Elicits Responses With Acceptable Safety in R/R Myeloma

August 30th 2023

Treatment with combination of mezigdomide and dexamethasone produced responses with a safety profile that consisted primarily of myelotoxic adverse effects in heavily pretreated patients with relapsed/refractory multiple myeloma.

Dara-KRd Quadruplet Makes Waves in Newly Diagnosed Multiple Myeloma

August 25th 2023

Luciano J. Costa, MD, PhD, discussed extended follow-up data from the trial and explained how the results may affect frontline treatment decisions in multiple myeloma.